• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Discontinuing Antipsychotics May Decrease Mortality Risk in Dementia

Discontinuing Antipsychotics May Decrease Mortality Risk in Dementia

May 1, 2009
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Section editor, Glen Spielmans, PhD

In a 2005 public health advisory, the FDA warned that antipsychotics appear to increase the rate of mortality in elderly patients with dementia. The implication is that we should discontinue such agents in this population when possible. But does this actually decrease the mortality risk? A recent randomized trial attempted to answer this question. In this study, 165 patients with dementia who were already taking antipsychotics were randomly assigned to either continue their antipsychotic regimen or switch to placebo for one year. During that year, more of the patients taking an antipsychotic died of any cause (30%) than did those taking placebo (23%). After a year, the randomized treatments were dis- continued and patients were placed on treatment as deemed appropriate by their physicians. When the original two groups were compared after three and a half years (42 months), there were significantly more survivors from the placebo group (53%) than from the antipsychotic group (26%) (Ballard C et al., 2009 Lancet Neurol 2009;8:151-157).

TCPR’s Take: The researchers did not track which medications were received by patients after the initial 12-month trial, so some of the patients in the placebo group likely restarted antipsychotics, while some patients who initially took antipsychotics may have discontinued them. That said, the group receiving antipsychotics during the 12-month trial quite likely had a greater cumulative exposure to the drugs than did the placebo group. Prior research has suggested minimal benefits and increased risk of mortality for antipsychotics in treating dementia (Schneider et al., 2006 Am J Geriatr Psychiatry;14:191-210). The bottom line is that we should minimize demented patients’ exposure to antipsychotic medications.

General Psychiatry
KEYWORDS antipsychotics
    www.thecarlatreport.com
    Issue Date: May 1, 2009
    SUBSCRIBE NOW
    Table Of Contents
    Effective Psychiatric Medications for Eating Disorders
    Psychotherapy for Eating Disorders: A Review of the Current Evidence
    Study Investigates Long-Term Course of ADHD
    Tips on Treating Eating Disordered Patients
    Predictors of Suicidal Behavior in Adolescent Treatment-Resistant Depression
    Discontinuing Antipsychotics May Decrease Mortality Risk in Dementia
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.